PharmaCyte Reaches 49.99% Stake in Q/C Technologies Through Warrant Exchange
QCLS is trading near its 52-week low of $0.275 (1.8% above the low).
Summary
PharmaCyte exchanged 851,304 Series G warrants for 4,982,272 Q/C Technologies shares at an implied $0.3101, reaching a 49.99% beneficial stake. Charters were amended to cap it there, and Series H maturity was pushed to September 2027.
Key Events · Ownership and Investor Activity · QCLS
-
Warrant Exchange Creates 49.99% Holder
PharmaCyte exchanged 851,304 Series G Long-Term Warrants for 4,982,272 common shares, valuing the exchange at $0.3101 per share (Black-Scholes value divided by the prior closing price).
-
Ownership Math and Share Base
Beneficial ownership totals 8,446,093 shares (5,152,000 held plus 3,294,093 acquirable within 60 days), or 49.99% of a base of 8,619,201 outstanding plus 4,982,272 exchange shares plus 3,294,093 acquirable shares.
-
Charter Caps and Maturity Extension
The November 20 Omnibus Amendment adds a 49.99% beneficial ownership limitation to the Series G and Series H charters and Series G warrants, and extends Series H maturity from March 2, 2027 to September 2, 2027.
-
Context: Nasdaq Bid Deficiency
Follows the November 13 8-K disclosing a November 6 Nasdaq notice that QCLS traded below $1.00 for 30 consecutive days; the stock is at $0.28.
Analysis · QCLS · Life Sciences
PharmaCyte converted 851,304 Series G Long-Term Warrants into 4,982,272 common shares at an implied $0.3101 per share, lifting its beneficial ownership to 8,446,093 shares — 49.99% of the class. That is a controlling-level stake in a company with a $2.4M market cap trading near its 52-week low, and it comes days after a Nasdaq $1.00 bid deficiency notice. The same-day Omnibus Amendment caps PharmaCyte at 49.99% and extends Series H maturity to September 2, 2027, so the overhang is now bounded but the concentration risk is real: one holder effectively controls the equity.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QCLS was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.28 to $8.17. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.